PROFOUND MEDICAL CORP. Financing Cash Flow
PROFOUND MEDICAL CORP. (PROF) reported Financing Cash Flow of $41.14 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- PROFOUND MEDICAL CORP. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $41.43M, a 16.91% increase year-over-year.
- PROFOUND MEDICAL CORP. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00.
- PROFOUND MEDICAL CORP. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $0.00.
- PROFOUND MEDICAL CORP. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was -$290.00K, a 101.42% decline year-over-year.
- PROFOUND MEDICAL CORP. net cash provided by (used in) financing activities for fiscal 2025 was $41.14M, a 24.79% decline from fiscal 2024.
- PROFOUND MEDICAL CORP. net cash provided by (used in) financing activities for fiscal 2024 was $54.70M, a 3014.81% increase from fiscal 2023.
- PROFOUND MEDICAL CORP. net cash provided by (used in) financing activities for fiscal 2023 was $1.76M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $41.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $41.43M derived: sum of 2 quarters · filed 2026-03-05 | $41.43M derived: sum of 3 quarters · filed 2026-08-06 | $41.14M 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | -$290.00K 10-Q · filed 2025-11-13 | $35.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$290.00K 10-Q · filed 2026-08-06 | $35.15M derived: sum of 3 quarters · filed 2026-08-06 | $34.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$290.00K 10-Q · filed 2026-05-07 | $35.15M derived: sum of 2 quarters · filed 2026-05-07 | $34.55M derived: sum of 3 quarters · filed 2026-05-07 | $33.95M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $35.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $34.84M derived: sum of 2 quarters · filed 2026-03-05 | $34.24M derived: sum of 3 quarters · filed 2026-03-05 | $54.70M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$592.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.20M derived: sum of 2 quarters · filed 2025-11-13 | $19.26M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$603.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $19.85M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $20.46M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $1.76M 10-K · filed 2025-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |